275eP The clinical impact of minimal residual disease (MRD) testing on the decision-making process in non-small cell lung cancer (NSCLC)

R. Gillis; Afifi Basel; A. Yaacov; R. Bashir; Noam Asna; N. Peled; E. Dudnik

doi:10.1016/j.esmoop.2026.106583

March 17, 2026ESMO OpenOpen Access

275eP The clinical impact of minimal residual disease (MRD) testing on the decision-making process in non-small cell lung cancer (NSCLC)

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to assess the clinical impact of minimal residual disease (MRD) testing on treatment decisions for non-small cell lung cancer (NSCLC).
Evaluated the feasibility of MRD testing in a real-world clinical setting.
Analyzed decision-making changes in treatment strategies based on MRD findings.
Collected data on patient outcomes related to MRD assessment.
MRD testing was found to be feasible in a clinical context.
Significant changes in treatment decisions were observed following MRD assessment.
MRD presence correlated with increased risk of relapse in NSCLC patients.

Implication

Evaluation reveals MRD testing influences decision-making in NSCLC, highlighting its potential role in treatment strategies.

Abstract

Minimal residual disease (MRD) assessment is an emerging tool for refining risk of relapse following definitive therapy in non-small cell lung cancer (NSCLC). However, data regarding its clinical impact on decision-making process remains limited. We evaluated MRD feasibility and impact in the real-world setting.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gillis et al. (2026) studied this question.

synapsesocial.com/papers/69bb9300496e729e62980cdb https://doi.org/10.1016/j.esmoop.2026.106583

View Full Paper

Ask AI

Bookmark

Share

275eP The clinical impact of minimal residual disease (MRD) testing on the decision-making process in non-small cell lung cancer (NSCLC)

Key Points

Implication

Abstract

Discussion

Cite This Study

275eP The clinical impact of minimal residual disease (MRD) testing on the decision-making process in non-small cell lung cancer (NSCLC)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading